MTV: TRL Christmas

Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, MTV: TRL Christmas, Malignancy, Safety, Fasting, Heart, Risk, AHA, Hypertriglyceridemia, TGS, Apolipoprotein B, Serum, Cleveland Clinic, Baylor College of Medicine, APOC3, American Heart Association, Dyslipidemia, MD, Triglyceride, Doctor of Philosophy, ASCVD, Arrowhead Pharmaceuticals, ANGPTL3, Moyamoya disease, Pharmaceutical industry, Shipbuilding, Medical device, Arrowhead, Medicine, Patient

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zodasiran (ARO-ANG3) at the American Heart Association (AHA) Scientific Sessions 2023, being held in Philadelphia, PA, on November 11-13, 2023.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zodasiran (ARO-ANG3) at the American Heart Association (AHA) Scientific Sessions 2023, being held in Philadelphia, PA, on November 11-13, 2023.
  • Despite potent LDL-C lowering therapies, residual ASCVD risk persists due in part to high levels of atherogenic TRLs.
  • At 24 weeks, plozasiran durably decreased serum APOC3 to -79%, TGs to -74%, and remnant cholesterol to -63%, while increasing HDL-cholesterol to +68%.
  • Serious TEAEs were not related to plozasiran and were resolved without sequelae, except two subjects with malignancies.

Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
Stock, Cardiovascular disease, ANGPTL3, European Society of Cardiology, Medicine, Research, TRL, RNA, Lipoprotein(a), MTV: TRL Christmas, Aortic stenosis, Thrombosis, Congress, Patient, Risk, Blood, LDL, Hart–Scott–Rodino Antitrust Improvements Act, PCSK9, Mouse, United Kingdom, Liver, Eli Lilly and Company, ASCVD, LDLR, ESC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Stroke, Pharmaceutical industry, Vaccine, Lilly, Verve

BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported recent company progress and financial results for the second quarter of 2023.

Key Points: 
  • Lp(a) Program Advancing in Collaboration with Lilly; Received $60 Million in Combined Upfront Payment and Equity Investment in August 2023
    BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported recent company progress and financial results for the second quarter of 2023.
  • “We are dedicated to bringing life-changing, once-and-done medicines to patients with cardiovascular disease,” said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve.
  • Finally, we are thrilled to advance our Lp(a) program in collaboration with Lilly, an industry leader in cardiometabolic disease.
  • Based on the progress of the heart-1 clinical trial, the company expects enrollment to be completed outside the United States.

Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023
ACC, Research and development, The First Half of My Life, Cardiovascular disease, Gene editing, FH, ANGPTL3, G&A, TRL, RNA, Low-density lipoprotein, MTV: TRL Christmas, Clinical trial, Patient, Administration, Blood, LDL, Annual general meeting, PCSK9, Mouse, ASCVD, LDLR, Moyamoya disease, LNP, American College, R, General Administration of Sport of China, Lancet, Death, IND, Asialoglycoprotein receptor, Conference, Food, Safety, Vaccine, Pharmaceutical industry, Video game, Verve

BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported pipeline progress and financial results for the first quarter of 2023.

Key Points: 
  • “The focus at Verve is to develop life-changing medicines for people with cardiovascular disease,” said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve.
  • When we started, we took what was a new base editing technology and an in-licensed lipid nanoparticle (LNP) and created VERVE-101.
  • Research & Development (R&D) Expenses: R&D expenses were $47.1 million for the first quarter of 2023, compared to $24.5 million for the first quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $12.6 million for the first quarter of 2023, compared to $7.4 million for the first quarter of 2022.

Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates

Retrieved on: 
Friday, March 3, 2023
Patient, MTV: TRL Christmas, Physiology, RNA, LDL, Clinical trial, ANGPTL3, PCSK9, DNA, Blood, Liver, Triglyceride, LDLR, LNP (newspaper), NHP, Primate, Asialoglycoprotein receptor, Initiation, ASCVD, Cardiovascular disease, LNP, Drug, Vaccine, Copper, Dietary supplement, Mouse, Verve

BOSTON, March 03, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported new preclinical data in non-human primates (NHPs) demonstrating potent, durable and well-tolerated editing of the ANGPTL3 gene following administration of VERVE-201.

Key Points: 
  • “ASCVD is not only a devastating but also a challenging group of indications to treat, requiring multiple treatment options for patients.
  • Patients with HoFH have severe or complete LDLR deficiency, which limits the ability of traditional LNPs to deliver base editing medicines to the liver.
  • Verve first developed LDLR-deficient NHPs (n=4), resulting in an increase in mean LDL-C from 55 to 458 mg/dL.
  • Presentation Title: Preclinical Data Supporting Potential Efficacy of Verve-201 - An Investigational CRISPR Base Editing Medicine Targeting ANGPTL3 - In Primary Human Cells, Mice, And Non-Human Primates